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Key points: 
 
Role of ongoing support for people with diabetes can improve glycaemic control with results 
seen comparable to treatment with expensive pharmacological agents 
 
Weight management groups can offer this support, and help obese people with diabetes 
manage their weight and glycaemic control 
 
Healthcare encouragement increases physical activity levels which may further enhance 
weight management and glycaemic control. 
 
Accessible group support external to traditional healthcare models should be considered as 
part of diabetes care and education. 
 
 
 
 
 
 
 
 
Abstract 
Healthcare professionals could work in partnership with commercial group weight 
management programmes (CGWMP) to help people with diabetes lose weight and improve 
their glycaemic control. The effect of ongoing CGWMP support on diabetes control has not 
previously been reported. This study evaluates weight loss and glycaemic control in people 
with diabetes attending a CGWMP. 
 
Method: A cross-sectional online survey posted on a CGWMP’s member’s website. The 
survey asked for reported changes in HbA1c and physical activity and demographics 
including age, type of diabetes, medications taken and healthcare professional support. The 
dataset was linked to electronically reported weight and attendances. Data was statistically 
analyzed to assess percentage of individuals meeting targets for weight reduction and HbA1c 
and outcome changes with variation between genders, type of diabetes and support.  
 
Results: 620 respondents with mean weight loss of 10.0±8.0%; 157 reported a mean reduction 
in HbA1c of 18±21mmol/mol (1.6±1.9%). 58.2% lost >10% body weight after 24 weeks and 
51.5% had achieved HbA1c of <48mmol/l (6.5%).  Those with type 2 (n=547) had greater 
reduction in HbA1c (p=0.034) but not weight (p=0.317) compared to type 1 diabetes (n=73). 
An increase in physical activity was associated with advise from a healthcare professional 
(p<0.001) with increases in PA not associated with lower HbA1c (p=0.654). A >5% weight 
reduction was associated with diabetes medication reduction (p=0.028) and improved 
glycaemic control (p=0.001). 
 
Conclusion: Support provided by the CGWMP resulted in clinically significant weight losses 
and improvements in HbA1c with reductions in diabetes medication. Attendance at CGWMPs 
may be an effective long-term strategy and a scalable option to help improve diabetes control. 
  
Introduction 
Sustainable, scalable and cost effective approaches reducing chronic health risks associated 
with diabetes and obesity are required. Group education, emphasising self-management and 
maintenance of weight loss, is an accepted approach (NICE, 2015). Currently most UK 
diabetes and weight management education is short-term with local variation but diabetes is a 
lifelong condition and people are likely to benefit from access to on-going support. There are 
few ongoing group based programmes for people with diabetes, which are scalable, with 
evidence of long-term effectiveness (Brown et al, 2015).  
 
Commercial group weight management programme (CGWMP) provider organisations are well 
placed to work in partnership with healthcare professionals to help people with diabetes lose 
weight and improve their glycaemic control. However, the effect of ongoing membership of a 
CGWMP on diabetes control has not previously been described.  
 
This study evaluates the electronically reported weight changes in a subgroup of people with 
diabetes (both T1DM and T2DM) attending a CGWMP. The self-reported changes in 
glycaemic control (HbA1c) were compared against current clinical standards set by NICE 
(2015). Changes in levels of physical activity and diabetes medication were investigated.  
 
Materials and Methods 
A combination of a cross-sectional online survey, posted on the members’ only section of 
Slimming World’s website between 21st July and 9th August 2013, and data collected through 
the CGWMP provider’s electronic weight record system were linked and analysed. The survey 
consisted of questions exploring type of diabetes, duration of diabetes, and glycaemic control 
with reported HbA1c at the time of joining and current values. In addition demographics 
including age and gender were requested alongside self-reported changes in physical activity 
levels, information about changes in medications taken to improve glycaemic control and 
support received from healthcare professionals.  
 
The survey was designed specifically for this study, with the intention of being easy to 
complete and in language with which the participants attending the programme were familiar. 
The questionnaire was constructed and administered using Checkbox v4.4-Web Survey 
Software (Prezza Technologies, Inc, Watertown, MA, USA). Electronically recorded 
attendance and weight data (Seca scales, Birmingham, UK; calibrated to the nearest 200g) were 
collected and used to report weight changes over time. 
 
 Data were analysed using SPSS 22.0 (IBM, New York, NY, USA). Normality of continuous 
variables was assessed using the Kolmogorov–Smirnov test and appropriate parametric and 
nonparametric statistics were then used to describe the sample. Chi-squared and Kruskal-
Wallis tests were used to investigate the relationship between variables. Data was analysed on 
a per protocol basis. An ANOVA was undertaken to assess the effect of length of membership 
on weight loss, post-hoc analysis was undertaken using a Bonferroni correction. A p-value of 
<0.05 was taken as significance.  
 
Ethical permission to undertake the analysis was obtained from the University of Nottingham’s 
research ethics committee (School of Biosciences ref SB1516/15).  
 
Results 
A total of 620 members responded to the questionnaire. Table 1 shows the baseline 
characteristics. Responding members had a median length of membership of 6.0 months at 
point of survey (Range 0-24 months; IQR 11.0 months; mean value12±9.8 months). 
 
Respondents to the survey were 88% (n=546) female and 88% (n=547) reported having T2DM. 
On joining the CGWMP, there were differences between genders and those with T1DM and 
T2DM (Table 1). Members with T1DM were significantly younger, lighter with a lower Body 
Mass Index (BMI) and had a longer duration of diabetes (p<0.001). There were no significant 
differences in glycaemic control between genders (p=0.329), type of diabetes (p=0.501) or 
BMI (p=0.992). For all members who attended for 12-24 weeks (n=236) a mean weight loss 
of 12.2±7.0 kg was achieved. Members who attended for between 24-52 weeks (n=72) had a 
mean weight loss of 13.9±7.0kg and those attending for more than a year lost 15.4±15.6kg 
(n=99) (Tables 2 & 3). 
 
72.5% of survey respondents lost more than 5% of body weight in 12 weeks, with 24.4 % 
losing more than 10% of their initial body weight. At 24 weeks 58.2% of respondents had lost 
greater than 10% of their initial body weight. Of the 93 respondents who had been a member 
for at least 52 weeks, a similar percentage, 40% of those with T1DM and 61% with T2DM, 
had lost at least 10% of their body weight (Figure 2b).  Those who achieved >5% weight 
reduction were more likely to have their diabetes medication reduced (p=0.028) and improved 
glycaemic control (p=-0.001). 
 
157 (28%) respondents reported changes in HbA1c levels. There were no significant 
differences in HbA1c between those with T1DM and those with T2DM at baseline (Table 1) 
(p=0.501). The numbers reporting an HbA1c of <48 mmol/mol (6.5%) increased from 16.4% 
(n=177) at joining to 51.5% (n=161) at the time of the survey (figures 1 and 2a and b). Members 
with T1DM reported a smaller reduction in HbA1c compared to members with T2DM 
(p=0.034). For respondents with T2DM, less weight was lost if treated with insulin (2.4kg, 
p<0.05).  Despite a difference in weight loss, there were no differences between reductions in 
HbA1c (18±21mmol/mol (1.6±1.9%) for those managed with insulin, compared to 19±21 
mmol/mol (1.7±1.9%) for those not managed with insulin, p=0.758). Members reporting the 
use of any diabetes medications lost significantly less weight, mean difference of weight loss 
4.4kg (p<0.001, -13.9±11.8 versus -9.5±8.6kg ), however there were no differences with 
respect to improvement in HbA1c (-19±22(-1.7±2.0%)  compared to -16± 
14mmol/mol(1.5±1.9%)). 
 
Respondents who reported reducing their diabetes related medication reported a significantly 
greater reduction in HbA1c 24±22 mmol/mol (2.2±2.0%, n=83) compared to those who had 
not 13±18 mmol/mol (1.2±1.6%, n=73, p=0.001). When this was considered in terms of type 
of medication reduced there was no significant association with any type of medication 
(p=0.073). Respondents who reported reducing their diabetes medication lost a significantly 
greater percentage of their starting bodyweight, -10.9±7.2% (n=74) compared to -8.2±7.9% 
(n=74) for those who did not decrease their medication (p=0.028). The type of medication 
reduced did not affect the amount of weight loss (p=0.0249).  
 
Reported change in physical activity was examined as a potential confounding variable, with 
72.3% (n=448) of respondents reporting an increase in physical activity. Members who 
reported an increase in physical activity did not lose significantly more weight (11.9±10.5kg 
for those reporting increased physical activity compared with 8.5±8.2kg; p=0.094). Reporting 
an increase in physical activity was associated with being advised to lose weight by a healthcare 
professional (p<0.001), with those with T2DM being more likely to report an increase in 
physical activity than those with T1DM (p=0.001). Change in medication dose and decreases 
in insulin were not associated with an increase in physical activity (p=0.272). Reported 
increases in physical activity was not associated with an improved HbA1c (p=0. 654). 
 
Duration of membership, significantly increased weight loss (p<0.001) if greater than 12 
weeks, and the loss was maintained for at least one year, but the effect of duration of 
membership on HbA1c was not significant (p=0.126). 
 
Discussion 
Slimming World (SW) is the largest CGWMP in the UK, currently running 16,000 group 
sessions each week, reaching 800,000 members weekly. It is estimated that approximately 10% 
of this number may have diabetes. Groups are located in a variety of local community venues 
throughout the UK across a range of days and times, making the groups easily accessible. The 
group facilitators are supported by regularly updated resources and dietitians based at Head 
office. 
 
The majority of respondents had T2DM and with a starting BMI of over 39kg/m2. This 
pragmatic evaluation, using an on-line survey, reports significant weight loss and 
improvements in glycaemic control, as measured by self-reported changes in HbA1c levels, in 
people with both T1 and T2DM attending the CGWMP. Reductions in weight and improved 
glycaemic control were associated with reduced need for diabetes medication. Although a self-
selecting sample, with a current median membership of 6 months, this study provides evidence 
that long term management can improve the key markers of weight and HbA1c whilst reducing 
medication requirements. Although length of membership does not increase reductions in 
HbA1c, it supports the suggestion that improvements in glycaemic control are maintained. This 
is concordant with the findings of Trento and colleagues (2010) that diabetes is not necessarily, 
with good self-management, a progressive condition.  
 
Currently in the UK only Orlistat is licensed for weight management and although caution 
needs to be taken in comparing this evaluation with a randomized controlled trial, 72.5% of 
respondents lost at least 5% of body weight at 12 weeks which increased to 81.3% at 24 weeks. 
This compares to 51.3% at 1 year for Orlistat (compared to 31.6% for placebo) in a population 
with T2DM (Hanefield & Sachse, 2002).  
 
 The respondents reported a mean decrease in HbA1c of 18mmol/mol (1.6%), which is 
comparable to the 22mmol/mol (2.0%) reported in the DCCT study (1993) for T1DM and 
almost double that reported in the UKPDS study (1998), associated with a 50% reduction in 
microvascular complications in T1DM5 and 10% reduction in diabetes related deaths in 
T2DM6. In addition, this level of reduction exceeds that reported for emerging therapies for 
diabetes management including the sodium-glucose cotransport 2 inhibitors, (Kadowaki et al, 
2014), DPP-4 inhibitors, (Moses et al, 2014), and incretin mimetics and analogues, (Moretto 
et al, 2008). 
 
 There are few ongoing group NHS based programmes for obese people with diabetes, which 
are scalable, with evidence of long-term effectiveness. The data reported in this study can be 
compared with data from the subset of 142 patients with diabetes who completed the SLiM 6-
month programme facilitated by trained dietetic assistants. The mean weight loss reported for 
the SLiM programme was 5.7±6.9kg (p=0.001) with 30% of patients with diabetes achieving 
≥5% and 11% achieving ≥10% weight loss over the 6 months, with those who lost weight 
achieving a mean weight loss of 4.0±4.6%. A mean reduction in HbA1c of 4.0±14.8mmol/l 
was reported, representing a change from 64.0±18.2mmol/l at base-line to 60.1±15.5mmol/l at 
the end of the programme (Brown et al, 2015). 
 
Comparing data suggests that membership of weight management groups can provide valuable 
long term support for people with diabetes wishing to lose weight and improve their health. It 
should be recognized that improvements in health might not be entirely dependent on weight 
loss but might also be related to associated changes in dietary behaviours, not reported here, or 
increased physical activity levels. The group and peer support may also contribute to the weight 
loss maintenance reported and is an area requiring further exploration (MacLean et al, 2015). 
The findings may be of relevance to the quest to find scalable solutions to reduce HbA1c levels 
in people presenting with prediabetes. A CGBWMP offers a non-clinical support option, and 
as diabetes is a long-term condition requiring self-management, this in itself might explain 
some of its benefits and value. Diabetes UK (2015) have suggested that people with diabetes 
only spend a maximum of three hours a year with their healthcare team meaning that other 
sources of ongoing support, such as weight management group membership could support 
improved self-management. 
 
Future work should look to enhance partnership working between CGWMPs and diabetes 
teams (either in primary or secondary care) to better support people with diabetes. Adjusting 
medication is important not only to reduce risks associated with hypoglycaemia, but also to 
facilitate weight loss. Hypoglycaemia and over treatment with insulin and sulphonylureas have 
been associated with weight gain, linked to the need to consume additional food energy as 
carbohydrate to treat hypoglycaemia (DCCT, 2001). It is clear that both people with T1DM 
and T2DM can benefit from membership of a weight management programme, and more 
research needs to be undertaken on the best way of monitoring and reducing the potential risks 
including hypoglycaemia. Effective teamwork between the person with diabetes, their diabetes 
care team and the weight management organisation is vital to optimize safe and desired 
outcomes.  
 
 
Limitations  
This cross sectional survey represents a fluid sample of around 1% of the total number of 
people with diabetes attending SW groups. All were still attending the groups having been 
members for variable lengths of time. Thus, the results may not reflect the overall impact of 
the intervention. 
The use of self-reported retrospective information, apart from weight and attendance, is a 
potential limiting factor. The overall nature of self-reported studies of this type; means that the 
data may represent a self-selection bias, in that those who chose to participant may be those 
who achieve better outcomes in terms of weight and improvement in glycaemic control and 
therefore may be more likely to respond positively to survey requests. Although this is possible 
it is considered that online surveys are no more prone to this than paper based surveys (Weigold 
et al, 2013).  Therefore, a main limitation is the self-reported HbA1c which unlike the weight 
data could not be verified in this study, and should be an area of focus for future work. 
Adverse event reporting, especially the incidence of hypoglycaemia related to changes in 
dietary patterns and doses of insulin and sulphonylureas was not reported within the scope of 
this study. 
 
Although there are a number of methodological limitations to consider, the results suggest that 
attending a CGWMP is beneficial to people with diabetes. Although weight loss is known to 
improve HbA1c and reduce medication usage, it is also significant that these are not necessarily 
interdependent, and improved lifestyle behaviours associated with group attendance may 
explain the observations seen. This observation has been supported by other lifestyle 
interventions in groups with diabetes3 and warrants further investigation. 
 
Conclusion 
People with both T1DM and T2DM, who attend a CGWMP can achieve clinically significant 
weight loss and glycaemic control as measured by changes in HbA1c levels. Improvements in 
physical activity levels and decreases in diabetes medication can also be achieved. The data 
supports the role of healthcare professionals encouraging the person with diabetes to lose 
weight, with these individuals apparently experiencing better glycaemic control, and this 
partnership approach warrants further emphasis and exploration. Whilst it is important for 
prospective research to fully assess the role of CGWMPs in supporting the self-management 
of people with diabetes. The mean length of attendance suggests that CGWMPs may offer 
long-term support to both long-term conditions (diabetes and obesity) and given the 
infrastructure of these organisations, this may offer a scalable solution to the associated public 
health burden.  
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Figure legends; 
 
Figure 1: Percentage of survey respondents achieving the NICE target for HbA1c 
 
Figure 2a) and b): Percentage of survey respondents achieving the NICE target for 
pharmacological weight loss interventions of 5% and 10% of initial body weight. 
 
 
Table 1: Baseline demographics of the respondents to the survey. Data presented as means ± 
standard deviations, all data was found to be normally distributed (Kolgmorov-Smirnov p>0.05) and p 
values are for unpaired t-tests, significance taken at p<0.05 level. 
 All Members Members with T2DM Members 
with T1DM 
P value 
T2DM vs 
T1DM 
Total respondents 620 547 73 - 
Age 51.1±12.5 52.7±11.7 38.0±11.9 <0.001 
Gender (n) 
Total/Female/Male 620/546/74 547/477/70 73/69/4 - 
Gender (%) 
Female/Male 
88/12 87/13 95/5 - 
Duration diabetes 
(months) (n=619) 
101.4±100.0 
(n=546) 
81.9±69.6 
(n=73) 
246.1±156.9 
<0.001 
Recorded Body 
Mass Index (kg/m2) 
at joining  
(n=419) 
38.7±7.5 
(n=373) 
39.3±7.3 
(n=46) 
33.6±7.1 
<0.001 
Self-reported 
HbA1c at joining 
(mmol/mol) 
( %) 
(n=177) 
68±21 
8.4±1.9 
 
(n=138) 
67±22 
8.3±2.0 
(n=39) 
8.5±1.6 
0.50 
 
 
 
Table 2: Recorded data at point of survey along with changes in weight and glycaemic 
control. Data presented as means +/- standard deviations, all data was found to be normally 
distributed (Kolgmorov-Smirnov p>0.05) and p values are for unpaired t-tests, significance taken at 
p<0.05 level. As survey was open over a two week period, the average weight for members over this 
period was used. 
 
All Members 
Members 
with T2DM 
Members 
with T1DM 
P value 
T2DM vs 
T1DM 
Females 
Members 
Male  
Members 
P value 
Female vs 
Male 
Percentage 
weight loss 
(%) 
-10.0±8.0 -9.9±8.0 -11.2±8.0 0.32 -9.7±7.8 -12.0±8.9 0.06 
Self-reported 
HbA1c at 
time of 
survey 
(mmol/mol) 
(n=161) 
50±16 
(n=128) 
47±15 
(n=33) 
60±16 
<0.001 
(n=143) 
50.2±15.3 
(n=18) 
47.9±21.1 
0.58 
Self-reported 
change in 
HbA1c 
joining to 
survey 
(mmol/mol)  
   (%) 
(n=157) 
-18±21 
-1.6±1.9 
(n=123) 
-20±22 
1.8±2.0 
(n=34) 
-12±16 
1.1±1.5 
0.034 
(n=141) 
-18±20 
-1.6±1.8 
(n=16) 
-24±25 
-2.2±2.3 
0.21 
 
Table 3: Recorded weight loss and reported change in HbA1c according to length of 
membership at the time of survey. Data presented as means +/- standard deviations, all data 
was found to be normally distributed (Kolgmorov-Smirnov p>0.05) and p values are for ANOVA post-
hoc test with Bonferroni correction, following p<0.05 ANOVA result as indicated. Significance taken 
at p<0.05 level. As survey was open over a two week period, the average weight for members over 
this period was used. 
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 Figure 1: Percentage of survey respondents achieving the NICE target for HbA1c(<48mmol/l or 
<6.5%) . As data is cross-sectional, it is not possible to adjust for attendance; median attendance was 
6 months. n=138 for respondents with T2DM and 39 for respondents with T1DM reporting a HbA1c 
at time of joining, and n=128 for respondents with T2DM and 33 for respondents with T1DM at the 
time of survey reported a HbA1c. 
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